» Articles » PMID: 26388208

Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function

Overview
Journal J Pediatr
Specialty Pediatrics
Date 2015 Sep 22
PMID 26388208
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate several alternative measures of forced expiratory volume in 1 second percent predicted (FEV1 %pred) variability as potential predictors of future FEV1 %pred decline in patients with cystic fibrosis.

Study Design: We included 13,827 patients age ≥6 years from the Epidemiologic Study of Cystic Fibrosis 1994-2002 with ≥4 FEV1 %pred measurements spanning ≥366 days in both a 2-year baseline period and a 2-year follow-up period. We predicted change from best baseline FEV1 %pred to best follow-up FEV1 %pred and change from baseline to best in the second follow-up year by using multivariable regression stratified by 4 lung-disease stages. We assessed 5 measures of variability (some as deviations from the best and some as deviations from the trend line) both alone and after controlling for demographic and clinical factors and for the slope and level of FEV1 %pred.

Results: All 5 measures of FEV1 %pred variability were predictive, but the strongest predictor was median deviation from the best FEV1 %pred in the baseline period. The contribution to explanatory power (R(2)) was substantial and exceeded the total contribution of all other factors excluding the FEV1 %pred rate of decline. Adding the other variability measures provided minimal additional value.

Conclusions: Median deviation from the best FEV1 %pred is a simple metric that markedly improves prediction of FEV1 %pred decline even after the inclusion of demographic and clinical characteristics and the FEV1 %pred rate of decline. The routine calculation of this variability measure could allow clinicians to better identify patients at risk and therefore in need of increased intervention.

Citing Articles

Demographic factors associated with within-individual variability of lung function for adults with cystic fibrosis: A UK registry study.

Palma M, Keogh R, Carr S, Szczesniak R, Taylor-Robinson D, Wood A J Cyst Fibros. 2024; 23(5):936-942.

PMID: 38969604 PMC: 11409769. DOI: 10.1016/j.jcf.2024.05.013.


DYNAMIC RISK PREDICTION TRIGGERED BY INTERMEDIATE EVENTS USING SURVIVAL TREE ENSEMBLES.

Sun Y, Chiou S, Wu C, McGarry M, Huang C Ann Appl Stat. 2023; 17(2):1375-1397.

PMID: 37284167 PMC: 10241448. DOI: 10.1214/22-aoas1674.


Management of respiratory tract exacerbations in people with cystic fibrosis: Focus on imaging.

Landini N, Ciet P, Janssens H, Bertolo S, Ros M, Mattone M Front Pediatr. 2023; 10:1084313.

PMID: 36814432 PMC: 9940849. DOI: 10.3389/fped.2022.1084313.


Variation in lung function and clinical aspects in adults with cystic fibrosis.

Silva E, Durante C, Rossato D, Dalcin P, Ziegler B J Bras Pneumol. 2022; 48(4):e20220155.

PMID: 35894415 PMC: 9496463. DOI: 10.36416/1806-3756/e20220155.


Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV1 decline.

Aquino C, Rodrigues J, Silva-Filho L J Bras Pneumol. 2022; 48(3):e20210237.

PMID: 35674545 PMC: 9262437. DOI: 10.36416/1806-3756/e20210237.